Cargando…
Serum biochemical markers in lung cancer.
The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of con...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1978
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009624/ https://www.ncbi.nlm.nih.gov/pubmed/77672 |
_version_ | 1782136152562597888 |
---|---|
author | Burt, R. W. Ratcliffe, J. G. Stack, B. H. Cuthbert, J. Kennedy, R. S. Corker, C. S. Franchimont, P. Spilg, W. G. Stimson, W. H. |
author_facet | Burt, R. W. Ratcliffe, J. G. Stack, B. H. Cuthbert, J. Kennedy, R. S. Corker, C. S. Franchimont, P. Spilg, W. G. Stimson, W. H. |
author_sort | Burt, R. W. |
collection | PubMed |
description | The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of controls) were found as follows: carcinoembryonic antigen (CEA), 17%; pregnancy-associated alpha-macroglobulin (PAM), 16%; casein 14%; human chorionic gonadotrophin (HCG) 6%; alpha-foetoprotein (AFP), 1.5%. The prevalence of elevated CEA levels (but not other markers) was higher in patients with evidence of extra-thoracic tumour spread (23%) mainly due to anaplastic tumours and adenocarcinomas. A degree of concordance of elevated marker levels occurred with CEA, HCG, casein and AFP, but there was a striking discordance of elevated CEA and PAM levels. Simultaneous assays of CEA and PAM will detect the majority of patients with elevations of any of the markers studied, and are likely to be the most useful biochemical markers in following the response of lung tumours to therapy. |
format | Text |
id | pubmed-2009624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 1978 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-20096242009-09-10 Serum biochemical markers in lung cancer. Burt, R. W. Ratcliffe, J. G. Stack, B. H. Cuthbert, J. Kennedy, R. S. Corker, C. S. Franchimont, P. Spilg, W. G. Stimson, W. H. Br J Cancer Research Article The prevalence of elevated serum levels of 5 potential tumour-associated antigens was determined in patients with lung cancer sampled at the time of initial presentation, using age- and sex-matched patients with benign lung disease as controls. Elevated levels (greater than upper 95th centile of controls) were found as follows: carcinoembryonic antigen (CEA), 17%; pregnancy-associated alpha-macroglobulin (PAM), 16%; casein 14%; human chorionic gonadotrophin (HCG) 6%; alpha-foetoprotein (AFP), 1.5%. The prevalence of elevated CEA levels (but not other markers) was higher in patients with evidence of extra-thoracic tumour spread (23%) mainly due to anaplastic tumours and adenocarcinomas. A degree of concordance of elevated marker levels occurred with CEA, HCG, casein and AFP, but there was a striking discordance of elevated CEA and PAM levels. Simultaneous assays of CEA and PAM will detect the majority of patients with elevations of any of the markers studied, and are likely to be the most useful biochemical markers in following the response of lung tumours to therapy. Nature Publishing Group 1978-05 /pmc/articles/PMC2009624/ /pubmed/77672 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Research Article Burt, R. W. Ratcliffe, J. G. Stack, B. H. Cuthbert, J. Kennedy, R. S. Corker, C. S. Franchimont, P. Spilg, W. G. Stimson, W. H. Serum biochemical markers in lung cancer. |
title | Serum biochemical markers in lung cancer. |
title_full | Serum biochemical markers in lung cancer. |
title_fullStr | Serum biochemical markers in lung cancer. |
title_full_unstemmed | Serum biochemical markers in lung cancer. |
title_short | Serum biochemical markers in lung cancer. |
title_sort | serum biochemical markers in lung cancer. |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009624/ https://www.ncbi.nlm.nih.gov/pubmed/77672 |
work_keys_str_mv | AT burtrw serumbiochemicalmarkersinlungcancer AT ratcliffejg serumbiochemicalmarkersinlungcancer AT stackbh serumbiochemicalmarkersinlungcancer AT cuthbertj serumbiochemicalmarkersinlungcancer AT kennedyrs serumbiochemicalmarkersinlungcancer AT corkercs serumbiochemicalmarkersinlungcancer AT franchimontp serumbiochemicalmarkersinlungcancer AT spilgwg serumbiochemicalmarkersinlungcancer AT stimsonwh serumbiochemicalmarkersinlungcancer |